Radiosensitization โดย Epidermal Growth Factor Receptor Inhibitors
Abstract
การศึกษายาใหม่สำหรับโรคมะเร็ง ที่ได้รับความสนใจอย่างมากในปัจจุบัน คือ Epidermal Growth Factor Receptors ซึ่งเป็น Transmembrane tyrosine kinas receptor มีหน้าที่รับสัญญาณจากภายนอก เซลล์เข้ามาภายในเซลล์ผ่านเข้าไปใน Signal transduction pathways ทำให้เกิดการเปลี่ยนแปลงของ เซลล์มะเร็ง(1)
References
Mendelsohn J and Baselga J. Status of epidermal growth factor receptor antagonists in the biology and treatment of cancer. J Clin Oncol 2003;21:2787-2799.
Bonner J et al. Cetuximab prolongs survival in patients with locoregionally advanced squamous cell carcinoma of head and neck: a phase III study of high dose radiation therapy with or without cetuximab [abstract]. J Clin Oncol 2004;22:a5507.
Harari PM and Huang SM. Head and neck cancer as a clinical model for molecular targeting of therapy : combining EGFR blockade with radiation. Int J Radiat Oncol Biol Phys 2001;49:427-433.
Robert F et al. Phase I study of anti-epidermal growth factor receptor antibody cetuximab in combination with radiation therapy in patients with advanced head and neck cancer. J Clin Oncol 2001;19:3234-3243.
Bonner J et al. Continued response following treatment with IMC-C225, an EGFR MoAb, combined with RT in advanced head and neck malignancies [abstract]. In American Society of Clinical Oncology 36th Annual Meeting : May 2000;20-33;
New Orleans, LA.
Milas L et al. Role of Epidermal Growth Factor Receptor (EGFR) and its Inhibition in Radiotherapy. (Eds Nieder C et al.) Heidelberg: Springer. 2002.
Eriksen JG et al. The prognostic value of epidermal growth factor receptor is related to tumor differentiation and the overall treatment time of radiotherapy in squamous cell carcinoma of the head and neck. Int J Radiat Oncol Biol Phys 2004;58:561-566.
Huang SM et al. Modulation of radiation response and tumor-induced angiogenesis after epidermal growth factor receptor inhibition by ZD1839 (Iressa). Cancer Res 2002;62:4300-4306.
Hirata A et al. Direct inhibition of EGF receptor activation in vascular endothelial cells by gefitinib ('Iressa', ZD1839). Cancer Sci 2004;95:614-618.
Shintani S et al. Enhancement of tumor radioresponse by combined treatment with gefitinib (Iressa, ZD1839), and epidermal growth factor receptor tyrosine kinase inhibitor, is accompanied by inhibition of DNA damage repair and cell growth in
oral cancer. Int J Cancer 2003;107:1030-1037.
Huang SM and Harari PM. Modulation of radiation response after epidermal growth factor receptor blockade in squamous cell carcinomas : inhibition of damage repair, cell cycle kinetics, and tumor angiogenesis. Clin Cancer Res 6 : 2000;
2166-2174.
Grana TM et al. Rad mediates radioresistance through both phosphatidylinositol 3-kinase-dependent and Raf-dependent but mitogen-activated protein kinase/extracellular single-regulated kinase kinase-independent signaling pathways.
Cancer Res 2000;62:4142-4150.
Doss HH, Greco FA, Meluch AA, et al. Induction chemotherapy+gefitinib followed by concurrent chemotherapy/radiation therapy/gefitinib for patients (pts) with locally advanced squamous carcinoma of the head and neck: a phase I/II trial of
the Minnie Pearl Cancer Research Network [abstract]. J Clin Oncol 2006;24(Suppl). Abstract 5543.
Herchehnorn D, Dias FL, Ferreira CG, et al. Phase I/II study of erlotinib combined with cisplatin and radiotherapy for locally advanced squmaous cell carcinoma of the head and neck (SCCHN) [abstract]. J Clin Oncol. 2006;24(Suppl). Abstract
5575.
Harrington KJ, Bourhis J, Nutting CM, et al. A phase I, open-label study of lapatinib plus chemoradiation in patients with locally advanced plus chemoradiation in patients with locally advanced squamous cell carcinoma of the head and neck
(SCCHN) [abstract]. J Clin Oncol. 2006;24(Suppl). Abstract 5553.
Wong SJ, Agha S, Milligan M. Concurrent chemotherapy practice patterns for head and neck cancer: what is standard of care [abstract]? J Clin Oncol. 2006;24(suppl). Abstract 5542.
Bonner J et al. Cetuximab prolongs survival in patients with locoregionally advanced squamous cell carcinoma of head and neck: a phase III study of high dose radiation therapy with or without cetuximab [abstract]. J Clin Oncol 2004;22:a5507.
Harari PM and Huang SM. Head and neck cancer as a clinical model for molecular targeting of therapy : combining EGFR blockade with radiation. Int J Radiat Oncol Biol Phys 2001;49:427-433.
Robert F et al. Phase I study of anti-epidermal growth factor receptor antibody cetuximab in combination with radiation therapy in patients with advanced head and neck cancer. J Clin Oncol 2001;19:3234-3243.
Bonner J et al. Continued response following treatment with IMC-C225, an EGFR MoAb, combined with RT in advanced head and neck malignancies [abstract]. In American Society of Clinical Oncology 36th Annual Meeting : May 2000;20-33;
New Orleans, LA.
Milas L et al. Role of Epidermal Growth Factor Receptor (EGFR) and its Inhibition in Radiotherapy. (Eds Nieder C et al.) Heidelberg: Springer. 2002.
Eriksen JG et al. The prognostic value of epidermal growth factor receptor is related to tumor differentiation and the overall treatment time of radiotherapy in squamous cell carcinoma of the head and neck. Int J Radiat Oncol Biol Phys 2004;58:561-566.
Huang SM et al. Modulation of radiation response and tumor-induced angiogenesis after epidermal growth factor receptor inhibition by ZD1839 (Iressa). Cancer Res 2002;62:4300-4306.
Hirata A et al. Direct inhibition of EGF receptor activation in vascular endothelial cells by gefitinib ('Iressa', ZD1839). Cancer Sci 2004;95:614-618.
Shintani S et al. Enhancement of tumor radioresponse by combined treatment with gefitinib (Iressa, ZD1839), and epidermal growth factor receptor tyrosine kinase inhibitor, is accompanied by inhibition of DNA damage repair and cell growth in
oral cancer. Int J Cancer 2003;107:1030-1037.
Huang SM and Harari PM. Modulation of radiation response after epidermal growth factor receptor blockade in squamous cell carcinomas : inhibition of damage repair, cell cycle kinetics, and tumor angiogenesis. Clin Cancer Res 6 : 2000;
2166-2174.
Grana TM et al. Rad mediates radioresistance through both phosphatidylinositol 3-kinase-dependent and Raf-dependent but mitogen-activated protein kinase/extracellular single-regulated kinase kinase-independent signaling pathways.
Cancer Res 2000;62:4142-4150.
Doss HH, Greco FA, Meluch AA, et al. Induction chemotherapy+gefitinib followed by concurrent chemotherapy/radiation therapy/gefitinib for patients (pts) with locally advanced squamous carcinoma of the head and neck: a phase I/II trial of
the Minnie Pearl Cancer Research Network [abstract]. J Clin Oncol 2006;24(Suppl). Abstract 5543.
Herchehnorn D, Dias FL, Ferreira CG, et al. Phase I/II study of erlotinib combined with cisplatin and radiotherapy for locally advanced squmaous cell carcinoma of the head and neck (SCCHN) [abstract]. J Clin Oncol. 2006;24(Suppl). Abstract
5575.
Harrington KJ, Bourhis J, Nutting CM, et al. A phase I, open-label study of lapatinib plus chemoradiation in patients with locally advanced plus chemoradiation in patients with locally advanced squamous cell carcinoma of the head and neck
(SCCHN) [abstract]. J Clin Oncol. 2006;24(Suppl). Abstract 5553.
Wong SJ, Agha S, Milligan M. Concurrent chemotherapy practice patterns for head and neck cancer: what is standard of care [abstract]? J Clin Oncol. 2006;24(suppl). Abstract 5542.
Downloads
Published
2009-06-30
How to Cite
1.
หล่อวิทยา ว, สุขถมยา ว. Radiosensitization โดย Epidermal Growth Factor Receptor Inhibitors. J Thai Assn of Radiat Oncol [Internet]. 2009 Jun. 30 [cited 2024 Nov. 15];15(1):107-12. Available from: https://he01.tci-thaijo.org/index.php/jtaro/article/view/203545
Issue
Section
Review articles
License
บทความที่ได้รับการตีพิมพ์เป็นลิขสิทธิ์ของวารสารมะเร็งวิวัฒน์ ข้อความที่ปรากฏในบทความแต่ละเรื่องในวารสารวิชาการเล่มนี้เป็นความคิดเห็นส่วนตัวของผู้เขียนแต่ละท่านไม่เกี่ยวข้องกับ และบุคคลากรท่านอื่น ๆ ใน สมาคมฯ แต่อย่างใด ความรับผิดชอบองค์ประกอบทั้งหมดของบทความแต่ละเรื่องเป็นของผู้เขียนแต่ละท่าน หากมีความผิดพลาดใดๆ ผู้เขียนแต่ละท่านจะรับผิดชอบบทความของตนเองแต่ผู้เดียว
